Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1

This study has been completed.
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: September 1, 2005
Last updated: December 2, 2009
Last verified: December 2009

Many cocaine dependent individuals are also dependent on alcohol. Such individuals respond poorly to existing treatments and have received little research attention in the past. The purpose of this study is to determine whether the combination of naltrexone and disulfiram is useful in decreasing alcohol use and cravings in people diagnosed with both cocaine and alcohol dependence.

Condition Intervention Phase
Alcohol-Related Disorders
Cocaine-Related Disorders
Drug: Naltrexone
Drug: Disulfiram
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Two Medications, Disulfiram and Naltrexone, in the Treatment of Patients With Both Cocaine and Alcohol Dependence

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Amount of alcohol and drug use. [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Enrollment: 208
Study Start Date: September 1999
Study Completion Date: January 2008
Primary Completion Date: March 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Naltrexone
Drug: Naltrexone
Experimental: Disulfiram
Drug: Disulfiram
Experimental: Naltrexone and Disulfiram
Naltrexone and Disulfiram
Drug: Naltrexone Drug: Disulfiram
Placebo Comparator: Placebo
Drug: Placebo

Detailed Description:

Many cocaine dependent individuals are also dependent on alcohol. Such individuals respond poorly to existing treatments and have received little research attention in the past. Naltrexone and disulfiram are medications currently approved for treating alcohol dependence. These two medications have different mechanisms of action in the body. In combination they might be effective in treating individuals dually diagnosed with cocaine and alcohol dependence. The purpose of this study is to determine whether the combination of naltrexone and disulfiram is useful in decreasing alcohol cravings in individuals who are dependent on both cocaine and alcohol.

Participants in this 5-year, double-blind study will be randomly assigned to receive disulfiram, naltrexone, both, or placebo. Treatment will occur for a 3-month period, after which alcohol, cocaine use, and other biopsychosocial measures will be assessed at Months 6 and 9.


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Meets DSM-IV criteria for both alcohol and cocaine dependence, as determined by the Structured Clinical Interview(SCID-IV)
  • Successful completion of alcohol detoxification (i.e., 3 consecutive days of abstinence from alcohol)
  • Use of at least $100 worth of cocaine in the 30 days prior to enrollment
  • In the past 30 days, Subject used no less than $100 worth of cocaine and drank a minimum of 12 standard alcohol drinks/week (on average), having at least four days in 30 where at least four or more drinks were ingested, as determined by the Timeline Followback (TLFB) - adapted to collect daily cocaine use;
  • Able to commute to the treatment research center
  • Speaks, understands, and writes English
  • Understands and signs the informed consent.

Exclusion Criteria:

  • Abstinence from alcohol or cocaine for more than 30 days before signing consent form
  • Current DSM-IV diagnosis of any psychoactive substance dependence other than Alcohol, Cocaine or Nicotine dependence, as determined by the SCID;
  • Evidence of opiate use in the past 30 days as assessed by self-report and intake urine drug screen;
  • History of unstable or serious medical illness, including need for opioid analgesics;
  • Concomitant treatment with phenytoin or from same drug class, lithium, serotonin selective reuptake inhibitors, tricyclic antidepressants, MAOI's or narcotics; 6) Use of any investigational medication within the past 30 days;
  • Severe physical or medical illness such as AIDS, active hepatitis or significant hepatocellular injury as evidenced by elevated bilirubin levels;
  • Severe psychiatric symptoms, e.g., psychosis, suicidal or homicidal ideation or mania;
  • Female patients who are pregnant, nursing, or not using a reliable method of contraception. Acceptable methods of birth control include: barrier (diaphragm or condom) with spermicide, intrauterine progesterone contraceptive system, levonorgestrel implant, medroxyprogesterone acetate contraceptive injection, oral contraceptives.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00142844

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
University of Pennsylvania
Principal Investigator: Helen M Pettinati, Ph.D. University of Pennsylvania
  More Information

Additional Information:
Responsible Party: Helen Pettinati, Ph.D., University of Pennsylvania Treatment Research Cener Identifier: NCT00142844     History of Changes
Obsolete Identifiers: NCT00136162
Other Study ID Numbers: NIDA-12756-1, P50DA012756-01, DPMC
Study First Received: September 1, 2005
Last Updated: December 2, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Alcohol-Related Disorders
Cocaine-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Pathologic Processes
Substance-Related Disorders
Alcohol Deterrents
Central Nervous System Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Narcotic Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 20, 2014